The Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry.
Oct 1, 2024DOI: 10.1016/j.cardfail.2024.08.003Journal ArticleJCF
Written by: Jennifer RymerCayla PichanCourtney PageBrooke AlhantiDeepak L BhattAjar KocharDominick J AngiolilloMiguel DiazNeil J WimmerRon WaksmanLawrence AngRichard BachRonald JenkinsHijrah El-SabaeLeo BrothersE Magnus OhmanW Schuyler JonesJeffrey B WashamTracy Y WangDennis NarcisseMir B Basir
Find these authors on Roon
JR
Dr. Jennifer Rymer
Interventional & Peripheral Cards · Duke University
CP
Dr. Cayla Pichan
General Cardiology · UT Southwestern
Summary
INTRODUCTION: Little is known about the use of cangrelor in patients with myocardial infarction (MI) presenting with cardiogenic shock (CS).METHODS: CAMEO (Cangrelor in Acute MI: Effectiveness and Outcomes) is a multicenter observational registry evaluating platelet inhibition in patients with MI. We examined the duration of cangrelor infusion and the amount of time to transition from cangrelor to an oral P2Y12 inhibitor in patients with CS. We also assessed major adverse cardiovascular events (MACEs) and bleeding risks, stratified by dosage duration, time to transition and oral P2Y12 inhibitor potency.RESULTS: Among 2352 cangrelor-treated patients with MI, 249 patients were in CS. Among the patients with CS, 16 (6.4%) received the "bridge" infusion dose, 202 (81.1%) the PCI cangrelor infusion dose, and 30 (12.0%) had a combination of both infusion doses. Patients with CS had a median age of 66 years; 32% were women; 21% were Black patients; 35% had diabetes; 19% received thrombectomy; and 59% received mechanical circulatory support (MCS) (35% intra-aortic balloon pump, 27% Impella). The median duration of infusion was 3.9 (2-21.5 hours) in patients with CS and was 2 (1.6-3.1 hours) for all cangrelor-treated patients. The median duration of transition from cangrelor to oral P2Y12 inhibitor administration was 0.1 (-0.5-21.0 hours) for patients with CS. In multivariable modeling, chronic lung disease and the use of MCS and was associated with longer cangrelor infusions (defined as > 3.9 hours). Among cangrelor-treated patients with CS, 24.1% of these patients had a bleeding event, and 41.8% had a MACE event. After adjustment, a longer cangrelor infusion duration was associated with increased risk of bleeding (P < 0.05).CONCLUSIONS: The median duration of cangrelor infusion was longer for patients presenting with CS. Use of MCS was associated with longer cangrelor infusion durations in patients with CS. Further work is needed to understand the pharmacodynamics of antiplatelet agents in patients with CS.
CP
Dr. Cayla Pichan
Cardiology · General Non-Invasive CardiologyThe University of Texas Southwestern Medical CentercaylaDallas, TX, USA
